Figure 3.

Enhanced 661W cell viability with compound 4j upon tBHP exposure. 661W cells were treated with tBHP in the presence/absence of increasing concentrations of compound 4j (10–200 μM) or the σ₁ receptor ligand PTZ (20–100 μM) for 24 h before cell viability assessment. Cell viability was assessed using the MTT assay. Data are presented as mean ± standard deviation (SD) of triplicate measurements; *p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significant as compared to the tBHP treatment. (tBHP = tert-butyl hydroperoxide; MRP = compound 4j; PTZ = (+)-pentazocine.)